Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LB1410 plus lenvatinib with or without LB4330 versus investigator's choice chemotherapy in recurrent/metastatic cervical cancer
CTR20253433Phase 2Active
- Sponsor
- L&L Biopharma Co., Ltd.
- Start
- Oct 2025
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of LB1410, lenvatinib and LB4330 in Cervical Cancer (CC) (3 arms), sponsored by L&L Biopharma Co., Ltd. Primary endpoint: Objective response rate by IRRC. Started Oct 2025; status: active.
02
Drugs
LB1410lenvatinibLB4330
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on CTR20253433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253433.